Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is scheduled to be releasing its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect Hims & Hers Health to post earnings of $0.02 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The firm’s quarterly revenue was up 47.4% on a year-over-year basis. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $11.25 on Friday. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -103.27 and a beta of 0.97. The firm’s 50-day moving average is $13.97 and its two-hundred day moving average is $10.22. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 50,361 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hims & Hers Health news, insider Irene Becklund sold 2,747 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $12.08, for a total transaction of $33,183.76. Following the completion of the sale, the insider now directly owns 5,494 shares in the company, valued at approximately $66,367.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 50,361 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total value of $822,898.74. The disclosure for this sale can be found here. Insiders sold a total of 736,191 shares of company stock worth $9,733,700 in the last three months. Company insiders own 31.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Tigress Financial lifted their price objective on shares of Hims & Hers Health from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 5th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. SVB Leerink initiated coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Finally, Imperial Capital upgraded shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price for the company in a research note on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.85.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.